Role of genetics in lung transplant complications

References

• Verleden GM. Chronic allograft rejection (obliterative bronchiolitis). Semin Respir Crit Care Med. 2001;22:551–8.
   Google Scholar
• Burlingham WJ, Love RB, Jankowska-Gan E, Haynes LD, Xu Q, Bobadilla JL, et al. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest. 2007;117:3498–506.
   PubMed Web of Science ®Google Scholar
• Verleden GM, Raghu G, Meyer KC, Glanville AR, Corris P. A new classification system for chronic lung allograft dysfunction. J Heart Lung Transplant. 2014;33:127–33.
   PubMed Web of Science ®Google Scholar
• Vanaudenaerde BM, Dupont LJ, Wuyts WA, Verbeken EK, Meyts I, Bullens DM, et al. The role of interleukin-17 during acute rejection after lung transplantation. Eur Respir J. 2006;27:779–87.
   PubMed Web of Science ®Google Scholar
• Boehler A, Kesten S, Weder W, Speich R. Bronchiolitis obliterans after lung transplantation: a review. Chest. 1998;114:1411–26.
   PubMed Web of Science ®Google Scholar
• Yusen RD, Christie JD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Adult Lung and Heart-Lung Transplant Report--2013; focus theme: age. J Heart Lung Transplant. 2013;32:965–78.
   Google Scholar
• Manolio TA. Genomewide association studies and assessment of the risk of disease. N Engl J Med. 2010;363:166–76.
   PubMed Web of Science ®Google Scholar
• Wain LV, Armour JA, Tobin MD. Genomic copy number variation, human health, and disease. Lancet. 2009;374:340–50.
   PubMed Web of Science ®Google Scholar
• Claustres M, Desgeorges M, Kjellberg P, Demaille J. Identification of carriers by screening for delta F508 deletion in a multi-generation cystic fibrosis family. Genet Couns. 1990;1:211–17.
   Google Scholar
• Hunninghake GM, Hatabu H, Okajima Y, Gao W, Dupuis J, Latourelle JC, et al. MUC5B promoter polymorphism and interstitial lung abnormalities. N Engl J Med. 2013;368:2192–200.
   PubMed Web of Science ®Google Scholar
• Christie JD, Carby M, Bag R, Corris P, Hertz M, Weill D. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: definition. A consensus statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2005;24:1454–9.
   PubMed Web of Science ®Google Scholar
• de Perrot M, Bonser RS, Dark J, Kelly RF, McGiffin D, Menza R, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part III: donor-related risk factors and markers. J Heart Lung Transplant. 2005;24:1460–7.
   PubMedGoogle Scholar
• Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol. 2005;23:337–66.
   PubMed Web of Science ®Google Scholar
• Diamond JM, Lederer DJ, Kawut SM, Lee J, Ahya VN, Bellamy S, et al. Elevated plasma long pentraxin-3 levels and primary graft dysfunction after lung transplantation for idiopathic pulmonary fibrosis. Am J Transplant. 2011;11:2517–22.
   PubMed Web of Science ®Google Scholar
• Konya V, Ullen A, Kampitsch N, Theiler A, Philipose S, Parzmair GP, et al. Endothelial E-type prostanoid 4 receptors promote barrier function and inhibit neutrophil trafficking. J Allergy Clin Immunol. 2013;131:532–40.
   Google Scholar
• Tang EH, Libby P, Vanhoutte PM, Xu A. Anti-inflammation therapy by activation of prostaglandin EP4 receptor in cardiovascular and other inflammatory diseases. J Cardiovasc Pharmacol. 2012;59:116–23.
   Google Scholar
• Diamond JM, Akimova T, Kazi A, Shah RJ, Cantu E, Feng R, et al. Genetic variation in the prostaglandin E2 pathway is associated with primary graft dysfunction. Am J Respir Crit Care Med. 2014;189:567–75.
   PubMed Web of Science ®Google Scholar
• Sharples LD, McNeil K, Stewart S, Wallwork J. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J Heart Lung Transplant. 2002;21:271–81.
   PubMed Web of Science ®Google Scholar
• Stewart S, Fishbein MC, Snell GI, Berry GJ, Boehler A, Burke MM, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant. 2007;26:1229–42.
   PubMed Web of Science ®Google Scholar
• Bonfield TL, Konstan MW, Burfeind P, Panuska JR, Hilliard JB, Berger M. Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis. Am J Respir Cell Mol Biol. 1995;13:257–61.
   PubMed Web of Science ®Google Scholar
• Awad MR, Webber S, Boyle G, Sturchioc C, Ahmed M, Martell J, et al. The effect of cytokine gene polymorphisms on pediatric heart allograft outcome. J Heart Lung Transplant. 2001;20:625–30.
   PubMed Web of Science ®Google Scholar
• Mazariegos GV, Reyes J, Webber SA, Thomson AW, Ostrowski L, Abmed M, et al. Cytokine gene polymorphisms in children successfully withdrawn from immunosuppression after liver transplantation. Transplantation. 2002;73:1342–5.
   Google Scholar
• Zheng HX, Burckart GJ, McCurry K, Webber S, Ristich J, Iacono A, et al. Interleukin-10 production genotype protects against acute persistent rejection after lung transplantation. J Heart Lung Transplant. 2004;23:541–6.
   PubMedGoogle Scholar
• Jackson A, Palmer S, Davis RD, Pappendick A, Pearson E, Savik K, et al. Cytokine genotypes in kidney, heart, and lung recipients: consequences for acute and chronic rejection. Transplant Proc. 2001;33:489–90.
   Google Scholar
• Palmer SM, Burch LH, Mir S, Smith SR, Kuo PC, Herczyk WF, et al. Donor polymorphisms in Toll-like receptor-4 influence the development of rejection after renal transplantation. Clin Transplant. 2006;20:30–6.
   PubMedGoogle Scholar
• Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol. 2001;1:135–45.
   PubMed Web of Science ®Google Scholar
• Barton GM, Medzhitov R. Control of adaptive immune responses by Toll-like receptors. Curr Opin Immunol. 2002;14:380–3.
   PubMed Web of Science ®Google Scholar
• Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet. 2000;25:187–91.
   PubMed Web of Science ®Google Scholar
• Palmer SM, Burch LH, Davis RD, Herczyk WF, Howell DN, Reinsmoen NL, et al. The role of innate immunity in acute allograft rejection after lung transplantation. Am J Respir Crit Care Med. 2003;168:628–32.
   PubMed Web of Science ®Google Scholar
• Triantafilou M, Triantafilou K. Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster. Trends Immunol. 2002;23:301–4.
   PubMed Web of Science ®Google Scholar
• Baldini M, Lohman IC, Halonen M, Erickson RP, Holt PG, Martinez FD. A Polymorphism* in the 5’ flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am J Respir Cell Mol Biol. 1999;20:976–83.
   PubMed Web of Science ®Google Scholar
• LeVan TD, Bloom JW, Bailey TJ, Karp CL, Halonen M, Martinez FD, et al. A common single nucleotide polymorphism in the CD14 promoter decreases the affinity of Sp protein binding and enhances transcriptional activity. J Immunol. 2001;167:5838–44.
   PubMed Web of Science ®Google Scholar
• Palmer SM, Klimecki W, Yu L, Reinsmoen NL, Snyder LD, Ganous TM, et al. Genetic regulation of rejection and survival following human lung transplantation by the innate immune receptor CD14. Am J Transplant. 2007;7:693–9.
   PubMed Web of Science ®Google Scholar
• Jin Y, Lee SJ, Minshall RD, Choi AM. Caveolin-1: a critical regulator of lung injury. Am J Physiol Lung Cell Mol Physiol. 2011;300:L151–60.
   PubMed Web of Science ®Google Scholar
• Vandermeulen E, Ruttens D, Verleden SE, Vos R, Van Raemdonck DE, Kastelijn EA, et al. Genetic variation in caveolin-1 affects survival after lung transplantation. Transplantation. 2014;98:354–9.
   Google Scholar
• Ruttens D, Verleden SE, Goeminne PC, Vandermeulen E, Wauters E, Cox B, et al. Genetic variation in immunoglobulin g receptor affects survival after lung transplantation. Am J Transplant. 2014;14:1672–7.
   Google Scholar
• Vanaudenaerde BM, Meyts I, Vos R, Geudens N, De Wever W, Verbeken EK, et al. A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy. Eur Respir J. 2008;32:832–43.
   PubMed Web of Science ®Google Scholar
• Ruttens D, Wauters E, Kicinski M, Verleden SE, Vandermeulen E, Vos R, et al. Genetic variation in interleukin-17 receptor A is functionally associated with chronic rejection after lung transplantation. J Heart Lung Transplant. 2013;32:1233–40.
   Google Scholar
• Mitsani D, Nguyen MH, Girnita DM, Spichty K, Kwak EJ, Silveira FP, et al. A polymorphism linked to elevated levels of interferon-γ is associated with an increased risk of cytomegalovirus disease among Caucasian lung transplant recipients at a single center. J Heart Lung Transplant. 2011; 30:523–9.
   Google Scholar
• Belperio JA, Weigt SS, Fishbein MC, Lynch JP III. Chronic lung allograft rejection: mechanisms and therapy. Proc Am Thorac Soc. 2009;6:108–21.
   PubMedGoogle Scholar
• Palmer SM, Burch LH, Trindade AJ, Davis RD, Herczyk WF, Reinsmoen NL, et al. Innate immunity influences long-term outcomes after human lung transplant. Am J Respir Crit Care Med. 2005;171:780–5.
   PubMed Web of Science ®Google Scholar
• Florescu DF, Kalil AC, Qiu F, Schmidt CM, Sandkovsky U. What is the impact of hypogammaglobulinemia on the rate of infections and survival in solid organ transplantation? A meta-analysis. Am J Transplant. 2013;13:2601–10.
   PubMed Web of Science ®Google Scholar
• Awad M, Pravica V, Perrey C, El Gamel A, Yonan N, Sinnott PJ, et al. CA repeat allele polymorphism in the first intron of the human interferon-gamma gene is associated with lung allograft fibrosis. Hum Immunol. 1999;60:343–6.
   Google Scholar
• Sempowski GD, Chess PR, Phipps RP. CD40 is a functional activation antigen and B7-independent T cell costimulatory molecule on normal human lung fibroblasts. J Immunol. 1997;158:4670–7.
   PubMed Web of Science ®Google Scholar
• Sporn MB, Roberts AB, Wakefield LM, Assoian RK. Transforming growth factor-beta: biological function and chemical structure. Science. 1986;233:532–4.
   PubMed Web of Science ®Google Scholar
• El-Gamel A, Awad MR, Hasleton PS, Yonan NA, Hutchinson JA, Campbell CS, et al. Transforming growth factor-beta (TGF-beta1) genotype and lung allograft fibrosis. J Heart Lung Transplant. 1999;18:517–23.
   PubMed Web of Science ®Google Scholar
• Awad MR, El-Gamel A, Hasleton P, Turner DM, Sinnott PJ, Hutchinson IV. Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation. 1998;66:1014–20.
   PubMed Web of Science ®Google Scholar
• Lu KC, Jaramillo A, Lecha RL, Schuessler RB, Aloush A, Trulock EP, et al. Interleukin-6 and interferon-gamma gene polymorphisms in the development of bronchiolitis obliterans syndrome after lung transplantation. Transplantation. 2002;74:1297–302.
   PubMedGoogle Scholar
• Snyder LD, Hartwig MG, Ganous T, Davis RD, Herczyk WF, Reinsmoen NL, et al. Cytokine gene polymorphisms are not associated with bronchiolitis obliterans syndrome or survival after lung transplant. J Heart Lung Transplant. 2006;25:1330–5.
   PubMed Web of Science ®Google Scholar
• Turner MW. Mannose-binding lectin: the pluripotent molecule of the innate immune system. Immunol Today. 1996;17:532–40.
   PubMedGoogle Scholar
• Bouwman LH, Roos A, Terpstra OT, de Knijff P, van Hoek B, Verspaget HW, et al. Mannose binding lectin gene polymorphisms confer a major risk for severe infections after liver transplantation. Gastroenterology. 2005;129:408–14.
   PubMed Web of Science ®Google Scholar
• Fiane AE, Ueland T, Simonsen S, Scott H, Endresen K, Gullestad L, et al. Low mannose-binding lectin and increased complement activation correlate to allograft vasculopathy, ischaemia, and rejection after human heart transplantation. Eur Heart J. 2005;26:1660–5.
   Google Scholar
• Munster JM, van der Bij W, Breukink MB, van der Steege G, Zuurman MW, Hepkema BG, et al. Association between donor MBL promoter haplotype and graft survival and the development of BOS after lung transplantation. Transplantation. 2008;86:1857–63.
   Google Scholar
• Kastelijn EA, van Moorsel CH, Rijkers GT, Ruven HJ, Karthaus V, Kwakkel-van Erp JM, et al. Polymorphisms in innate immunity genes associated with development of bronchiolitis obliterans after lung transplantation. J Heart Lung Transplant. 2010;29:665–71.
   PubMed Web of Science ®Google Scholar
• Parks WC, Shapiro SD. Matrix metalloproteinases in lung biology. Respir Res. 2001;2:10–19.
   PubMed Web of Science ®Google Scholar
• Kastelijn EA, van Moorsel CH, Ruven HJ, Karthaus V, Kwakkel-van Erp JM, van de Graaf EA, et al. Genetic polymorphisms in MMP7 and reduced serum levels associate with the development of bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant. 2010;29:680–6.
   PubMed Web of Science ®Google Scholar
• Kastelijn EA, van Moorsel CH, Kazemier KM, Roothaan SM, Ruven HJ, Kwakkel-van Erp JM, et al. A genetic polymorphism in the CAV1 gene associates with the development of bronchiolitis obliterans syndrome after lung transplantation. Fibrogenesis Tissue Repair. 2011;4:24.
   Google Scholar
• McCormack FX, Whitsett JA. The pulmonary collectins, SP-A and SP-D, orchestrate innate immunity in the lung. J Clin Invest. 2002; 109:707–12.
   PubMed Web of Science ®Google Scholar
• D’Ovidio F, Kaneda H, Chaparro C, Mura M, Lederer D, Di Angelo S, et al. Pilot study exploring lung allograft surfactant protein A (SP-A) expression in association with lung transplant outcome. Am J Transplant. 2013;13:2722–9.
   PubMed Web of Science ®Google Scholar
• Aramini B, Kim C, Diangelo S, Petersen E, Lederer DJ, Shah L, et al. Donor surfactant protein D (SP-D) polymorphisms are associated with lung transplant outcome. Am J Transplant. 2013;13:2130–6.
   PubMed Web of Science ®Google Scholar
• Singh G, Katyal SL. Clara cells and Clara cell 10 kD protein (CC10). Am J Respir Cell Mol Biol. 1997;17:141–3.
   PubMed Web of Science ®Google Scholar
• Bourdin A, Mifsud NA, Chanez B, McLean C, Chanez P, Snell G, et al. Donor clara cell secretory protein polymorphism is a risk factor for bronchiolitis obliterans syndrome after lung transplantation. Transplantation. 2012;94:652–8.
   Google Scholar
• Bird A. Perceptions of epigenetics. Nature. 2007;447:396–8.
   PubMed Web of Science ®Google Scholar
• Schildberg FA, Hagmann CA, Bohnert V, Tolba RH. Improved transplantation outcome by epigenetic changes. Transpl Immunol. 2010;23: 104–10.
   PubMedGoogle Scholar
• Anraku M, Cameron MJ, Waddell TK, Liu M, Arenovich T, Sato M, et al. Impact of human donor lung gene expression profiles on survival after lung transplantation: a case-control study. Am J Transplant. 2008;8: 2140–8.
   PubMedGoogle Scholar